InflaRx N.V. Forecast, price target & analysts
InflaRx N.V. Target price 2025 - Analyst rating & recommendation
InflaRx N.V. Classifications & Recommendation:
InflaRx N.V. Price Target
| Target Price | $4.34 |
| Price | $0.83 |
| Potential |
422.97%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target InflaRx N.V. 2026 .
The average InflaRx N.V. target price is $4.34.
This is
422.97%
register free of charge
$10.00
1,104.19%
register free of charge
$2.00
140.84%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend InflaRx N.V. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the InflaRx N.V. stock has an average upside potential 2026 of
422.97%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.19 | 0.43 |
| 171.43% | 126.11% | |
| Net Margin | -27,768.42% | -11,654.41% |
| 60.23% | 58.03% |
7 Analysts have issued a sales forecast InflaRx N.V. 2025 . The average InflaRx N.V. sales estimate is
This results in the following potential growth metrics:
4 InflaRx N.V. Analysts have issued a net profit forecast 2025. The average InflaRx N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.89 | -0.79 |
| 0.00% | 11.24% | |
| P/E | negative | |
| EV/Sales | negative |
4 Analysts have issued a InflaRx N.V. forecast for earnings per share. The average InflaRx N.V. EPS is
This results in the following potential growth metrics and future valuations:
Current InflaRx N.V. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 29 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 29 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Apr 29 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 16 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
